Don't know if anyone has been keeping up with my long time pick PPHM but she has gained sixty cents already this year. I look for this stock to get back over two bucks. IMO.

I would like to thank all the people that have been a part of this board. I wish each and everyone of you a Very Merry Christmas.

Hey Guys, I am still hanging in there with ya. I don't trade as much these days but I am still rolling FMDY and PPHM over now and then for some good profits. I see Lin has not been on here for some time now so I made SS and Walk a mod to help out on here. These two guys have been with me from the start so please respect what they say and do.

Thanks SS & Walk for all your help.


Welcome to all the new traders on here. Sorry I missed ya when you came in but work has been keeping me away for the boards. Keep them picks coming and keep up the good work.

FMDAY News:

(PR NEWSWIRE) Futuremedia Awarded e-Learning Contract by Barclays
Futuremedia Awarded e-Learning Contract by Barclays

BRIGHTON, England, April 25 /PRNewswire-FirstCall/ -- Futuremedia plc
(Nasdaq: FMDAY), a leading European e-learning content and services provider,
today announced the launch of a learning portal for the Barclays Wealth
Academy, building a community of wealth professionals within Barclays Private
Clients division. This division offers a range of financial services to
Barclays high net worth clients, including private banking, estate planning
and stockbroking.
The design and development of the portal, created in partnership with
Barclays, carries a large amount of learning content provided by wealth
experts -- allowing users to tap into existing expertise from within and
outside the Barclays organization. Together with the opportunity for two-way
communication to all of Barclays Private Clients staff, some 7,000 employees,
it provides just-in-time access to knowledge and best practice.
Paul Rudd, Director of the Wealth Academy said, "We are delighted to
announce the launch of this initiative, which will help our wealth managers
provide up-to-date, technically correct advice and excellent client service.
The portal has been implemented at great pace -- in only six weeks, which is a
record for the creation of a sophisticated learning solution within Barclays,
but everything we have done has been validated at senior level by the
business. The quality of the end product is a tribute to the rigorous design
processes that have been employed, and to our close relationship with the team
from Futuremedia. They responded with great professional ability to a complex
and difficult task."
Leonard M. Fertig, CEO of Futuremedia, said, "Our relationship with
Barclays Wealth Academy is proof of Futuremedia's ability to provide advanced
learning solutions for clients who demand answers to complex challenges, at
pace. Working alongside Barclays, we created the Wealth Academy portal in only
six weeks; its launch is the beginning of a number of community based learning
portals we are jointly developing."
About Barclays Wealth Management:
Barclays wealth management business sits within its Private Clients
division, and regards its people as fundamental to business success -- it is
critical they are of the right quality and have the right level of expertise.
This focus on quality has already ensured Private Clients is the leading
branded European affluent bank and the number one retail stockbroker. Barclays
Wealth Academy has been established, with its strapline of "mind enriching",
as a clear demonstration of commitment to developing employees.
About Futuremedia:
Futuremedia is a leading company in the e-Learning market with 20 years
experience in providing technology-based solutions to public and private
sector organizations. Services include: learning consultancy, custom made
learning programs, an extensive library of published courseware titles and
needs analysis and follow up of individual employees.
Futuremedia's customers include Britvic, BT, BUPA, Capita, the UK Crown
Prosecution Service, Channel Four, Daimler Chrysler, GSK, Hilton
International, IDEA, ING Direct, the UK National Health Service, Royal Mail,
Syngenta, Winterthur Life and a growing number of UK local authorities. The
Company is partnered with Fujitsu-Siemens, Microsoft, Thomson NETg and
SkillSoft in delivering its products and solutions.
"Safe Harbor" Statement under Section 21E of the Securities Exchange Act
of 1934: This press release contains forward-looking statements related to
future results and speaks only of Futuremedia's expectations as of the date
hereof. Such statements include the Company's future financial performance and
the future performance of the Company's products. Such statements involve
known and unknown risks and uncertainties that may cause actual results to
differ materially from expectations. The risks and uncertainties include risks
associated with new contracts (including the possibility that contracts may be
terminated or not completed due to factors beyond the Company's control),
risks associated with the Company's ability to develop and successfully market
new services and products (including products and services based on government
tax-benefit programs), the Company's ability to operate profitably in the
future, risks associated with rapid growth, the Company's ability to
successfully develop its business in new geographic markets, the early stage
of the e-learning market, rapid technological change and competition, and
other factors detailed in the Company's filings with the US Securities and
Exchange Commission. The Company expressly disclaims any obligation to release
publicly any updates or revisions to any such statement to reflect any change
in expectations or in information on which any such statement is based. All
product names and trademarks mentioned herein are trademarks of Futuremedia or
their respective owners.
SOURCE Futuremedia plc


Contact Information:
Mike Smargiassi, or Corey Kinger, both of Brainerd Communicators, Inc., +1-212-9
6-6667, or ir@futuremedia.co.uk, for Futuremedia plc

WebSite:
http://www.futuremedia.co.uk
*** end of story ***

PPHM making a nice move on News:

(COMTEX) B: Peregrine compound enhances multiple chemo drugs ( Datamonitor
)
B: Peregrine compound enhances multiple chemo drugs ( Datamonitor )

Apr 18, 2005 (Datamonitor via COMTEX) -- A recently published report has shown
that Peregrine Pharmaceuticals' NHS76/PEP2 enhances the efficacy of multiple
chemotherapeutic agents, including Bristol-Myers Squibb's Taxol, by up to
threefold.

Peregrine Pharmaceuticals today announced that a paper titled "NHS76/PEP2, a
Fully Human Vasopermeability-Enhancing Agent to Increase the Uptake and Efficacy
of Cancer Chemotherapy,"

The paper, which was published in the Clinical Cancer Research journal, shows
that NHS76/PEP2 greatly enhanced the uptake and efficacy of a variety of
chemotherapeutic agents in solid tumor models.

The publication contains data showing that pretreatment with NHS76/PEP2,
Peregrine's lead vasopermeability-enhancing agent (VEA), enhanced the efficacy
of chemotherapy in tumors known to be sensitive to the specific drugs. In
addition, the report shows that NHS76/PEP2 plus chemotherapy also generated
responses in tumors normally resistant to specific therapies, such as MAD109
murine lung carcinoma treated with paclitaxel (Taxol), vinblastine (Eli Lilly's
Velban) or 5-FU.

Moreover, improvements in drug uptake were seen in as little as one to two hours
following pretreatment with NHS76/PEP2.

NHS76/PEP2 is the result of a fusion protein between NHS76, a fully human
version of one of Peregrine's tumor necrosis therapy antibodies, and PEP2, a
peptide derived from interleukin 2.


URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

Copyright (C) 2005 Datamonitor. All rights reserved

-0-


KEYWORD: United States
SUBJECT CODE: All cancer
Pharmaceuticals
Healthcare biotechnology
Big Pharma
Healthcare R&D
Bristol-Myers Squibb Company
Eli Lilly and Company
Peregrine Pharmaceuticals, Inc.
Cancer, General

*** end of story ***

GTEL News:

(COMTEX) B: GTEL Unveils Sanswire One
B: GTEL Unveils Sanswire One

MIAMI, Apr 14, 2005 (BUSINESS WIRE) -- GlobeTel Communications Corp. (OTCBB:
GTEL), today announced that the unveiling of its high-altitude airship prototype
by its wholly-owned subsidiary, Sanswire Networks, LLC, generated a significant
amount of interest and positive feedback from the media and investors.

Over 300 people attended the unveiling of Sanswire One held on April 12, 2005,
including members of the media, personnel from the U.S. Department of Defense,
U.S. and international commercial interests, as well as investors and
shareholders. Among media personnel, there were representatives from The
Associated Press, Reuters, and television crews from the major networks and
cable news channels.

As of April 13, 2005, the unveiling was reported on TV and cable by numerous
national and local news affiliates throughout the country, beginning with Fox
News that broadcasted its coverage on the night of the unveiling. The unveiling
was also covered by the National Public Radio (NPR) and was featured in several
major newspapers including the New York Times and the Los Angeles Times.

Timothy M. Huff, CEO of GTEL, commented, "We are very excited about the coverage
Sanswire One has been getting from the media. We have been continually receiving
reports from our shareholders from all over the country about the local coverage
of the unveiling. In my opinion, the media is reporting on the progress of
Sanswire One as they recognize the potential of our airship and the potential of
causing what I always refer to as a paradigm shift in the telecommunications
industry."

Mr. Huff also gave credence to the work of the Sanswire engineering team, headed
by Bob Jones, former NASA Plans and Programs Manager along with several other
NASA and aerospace industry engineers who all left their place of employment to
join Mr. Jones at Sanswire. Mr. Huff stated, "We are extremely pleased with the
progress made by Bob and the rest of the Sanswire team. The team represents over
150 years of NASA and Air Force experience and they truly are a world class team
of experts. Bob left NASA to join us with only few years left from his NASA
retirement. This shows his belief in what we are trying to achieve at Sanswire.
His innovative approach and out-of- the-box thinking is enabling us to
successfully execute the program."

Mr. Jones, who is also President of Sanswire Governmental Services, stated that
the team has made substantial and significant improvements to the Airship
design. Commented Mr. Jones, "being with NASA for 25 years, I will be the first
to state that nothing new and significant is ever built, tested and completed
successfully the first time around. There will be trials and errors, changes and
more improvements that need to be made. However, we have locked down the
engineering and materials so we are confident that we will be able to continue
on a timeline that will be more measurable and attainable."

Mr. Jones reported that after detailed aerodynamic and structural analysis, the
team lengthened Sanswire One's frame to 188 feet from the original design of 90
feet. Eventually, the commercial airships, which were originally designed to be
245 feet, will range from 450 feet to 800 feet depending on payload
requirements. Mr. Jones continued, "In three weeks, we corrected the original
design and built almost 100 additional feet of the space frame. We also moved
from a Dacron covering to a space age Tedlar covering, developed a ground
station communications package, and made advances in composite materials and in
method of lifting gases."

According to Mr. Jones, the FAA has directed Sanswire to conduct the flight test
at the Edwards Air Force Test Range and that the Company is closely working with
the FAA and the Air Force for concession for the Airship to transition from FAA
controlled airspace at Palmdale to Edwards 2508 restricted airspace at Edwards
Air Force Base. This will enable Sanswire to further test the Airship at the Air
Force Flight Test Center and NASA Dryden Flight Research Center. Edwards Air
Force Base has been the location of many historical events in aerospace history,
including landing of the Space Shuttle and record breaking speeds.

Sanswire plans to do tethered test outside of the hanger at its current location
at San Bernardino Airport, California to validate the structural integrity and
to collect needed data. After the test, the airship will be transported to the
Palmdale secured hangar next to Edwards Air force Base. These tests will in no
way delay the process already underway to clear the airship for flight on the
test range at Edwards.

Mr. Jones also commented that clearance of many FAA and governmental processes
are necessary to enable Sanswire One to safely fly at the Air Force Flight Test
Center and NASA Dryden Flight Research Center. Currently, the FAA is working on
a process to allow unmanned aerial vehicles, such as Sanswire One, to safely
operate in the national air space. Also, the Air Force and NASA has their own
flight test and safety approval processes that must be accomplished. These
processes require additional time and resources to satisfy the governmental
agencies. All new aerospace vehicles, even military, must go through these
processes. These processes are in place to protect high value government and
public assets as well as the safety of the general public.

Mr. Huff also stated that "Sanswire is very proud to have built a strong team of
renowned aerospace professionals who are using their broad backgrounds and
technical skills to design and construct the world's first high altitude rigid
Airship. Our team and this overall project are paving the future of
communications.

Mr. Huff continued, "We have the attention of many divisions the Department of
Defense, multiple large commercial interest, many different governments around
the world, the science community, surveillance, border control and many others.
As Bob mentioned, there will be changes and improvements and while we may expect
surprises with Sanswire One as this has never been done before, we will do
everything we could to get this right the first time. We will not rush for the
sake of a timeline."

Mr. Huff concluded, "I will continue to try to keep everyone informed, but I
would also like to point out that any engineering changes and new technology
brought to the program, may affect the timeline but add value to the program. My
team and I are here to build a substantial company and that will take hard work
and time. In my opinion, we are still way ahead of the curve and with the
lockdown of the engineering and materials, together with our team's dedication,
we are well on our way to the successful launch of Sanswire One."

For more information, please go to http://www.globetel.net or
http://www.sanswire.com

Certain statements in this release constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking statements
within the meaning of the Private Placement Act of 1995. The words "forecast",
"project", "intend", "expect", "should", "would", and similar expressions and
all statements, which are not historical facts, are intended to identify
forward-looking statements. These forward-looking statements involve and are
subject to known and unknown risks, uncertainties and other factors which could
cause the Company's actual results, performance (finance or operating) or
achievements to differ from future results, performance (financing and
operating) or achievements expressed or implied by such forward-looking
statements. The above are more fully discussed in the Company's SEC filings.

SOURCE: GlobeTel Communications Corporation



CONTACT: GlobeTel Communications Corp., Pembroke Pines
Leigh Coleman, 954-241-0590
investors@globetel.net
http://www.globetel.net


Copyright Business Wire 2005

-0-


KEYWORD: United States
North America
Florida
INDUSTRY KEYWORD: Technology
Hardware
Telecommunications
Transport
Air
Manufacturing
Aerospace
SUBJECT CODE: Product/Service
Photo/Multimedia

*** end of story ***

GTEL making another good run this morning. Made a nice flip yesterday and fixing to make another one today.

Rolled the dice on FMDAY yesterday at .38 wish me luck.

(COMTEX) B: Futuremedia Announces Agreement with Dyson Limited to Provide
ome Computing Initiative Tax-Efficient Benefits Packa
B: Futuremedia Announces Agreement with Dyson Limited to Provide Home Computing
nitiative Tax-Efficient Benefits Package ( PRNewswire-FirstCall )

BRIGHTON, England, April 14, 2005 /PRNewswire-FirstCall via COMTEX/ --
Futuremedia plc (Nasdaq: FMDAY), a leading European e-learning content and
services provider, today announced an agreement with Dyson Limited, the creator
of the Dyson Cyclone vacuum cleaner, to provide home computers to all eligible
Dyson employees under the government's Home Computing Initiative (HCI).

The Futuremedia package gives employees the opportunity to lease an
Internet-ready, fully installed PC or the lease of an Apple computer at below
high street prices, typically a saving of 40%, for a period of three years.
Futuremedia expects to launch its first phase of the HCI program to Dyson
employees in April 2005.

Leonard M. Fertig, Chief Executive Officer of Futuremedia, said, "We are
delighted to partner with Dyson, an innovator and leader in its industry, in
providing these benefits to their more than 1,000 employees. Dyson
revolutionized the way people look at vacuum cleaners and is once again
exercising its leadership to its employees though this benefits program. Our
Learning For All(TM) (LFA) service offering has made Futuremedia a pioneer and
leader in the creation of HCI benefits packages and we continue to capitalize on
this position as we expand our client base."

Martin McCourt, Dyson's Chief Executive Officer, said, "This is an incredible
benefit that enables our employees to secure a home computer at a reduced price.
We selected Futuremedia as our partner due to their leadership and innovation in
the HCI field and we are pleased to provide our employees with their benefit
program."

About Dyson:

James Dyson invented and patented the Dyson Dual Cyclone(TM) vacuum cleaner
technology which uses centrifugal force and doesn't lose suction. With its
headquarters in Malmesbury, England, more than a quarter of its workforce are
scientists and engineers, creating better and different products and
technologies in Dyson's Research Design and Development Centre. Dyson has
received numerous awards for technological innovation including the Industrial
Design Prize of America, Chicago Athenaeum Good Design Prize, the European
Design Prize, the Super Good of the Year (Japan), the L'Etoile de l'Observeur du
Design (France) and was cited as one of Time magazine's "coolest inventions of
2003."

About Futuremedia:

Futuremedia plc is a leading provider of value-driven e-learning content and
services to employers and employees. The Company has a proven track record of
developing and providing tailored, fully managed outsourced benefit programs for
large organizations and is a leader in the UK's Home Computing Initiative
Program. Futuremedia's content and services offerings include learning
consultancy, Learning Management Systems, custom made learning programs and an
extensive library of published courseware titles.

Through its Learning For All(TM) (LFA) service offering, the Company is a
pioneer and leader in the creation, development and delivery of employee
benefits programs that fall under the government Home Computing Initiative
(HCI). A fully managed service, Futuremedia can provide employees with access to
an Internet-ready, fully installed home computer with on-line learning content
at a discounted cost through government tax incentives. Futuremedia currently
serves 20 corporations and institutions and over 27,000 enrolled employees
through its HCI initiatives. Futuremedia has also expanded its employee tax
benefits management program to include services offered under the childcare
voucher system and tax-free bicycle initiatives in the UK. Futuremedia Plc
appears on the official supplier listing of the HCI Alliance as a Founder HCI
Alliance Provider Partner. Please see the HCI Alliance website for the listing
criteria: http://www.ukhomecomputing.co.uk.

"Safe Harbor" Statement under Section 21E of the Securities Exchange Act of
1934: This press release contains forward-looking statements related to future
results and speaks only of Futuremedia's expectations as of the date hereof.
Such statements include the Company's future financial performance and the
future performance of the Company's products. Such statements involve known and
unknown risks and uncertainties that may cause actual results to differ
materially from expectations. The risks and uncertainties include risks
associated with new contracts (including the possibility that contracts may be
terminated or not completed due to factors beyond the Company's control), risks
associated with the Company's ability to develop and successfully market new
services and products (including products and services based on government
tax-benefit programs), the Company's ability to operate profitably in the
future, risks associated with rapid growth, the Company's ability to
successfully develop its business in new geographic markets, the early stage of
the e-learning market, rapid technological change and competition, and other
factors detailed in the Company's filings with the US Securities and Exchange
Commission. The Company expressly disclaims any obligation to release publicly
any updates or revisions to any such statement to reflect any change in
expectations or in information on which any such statement is based. All product
names and trademarks mentioned herein are trademarks of Futuremedia or their
respective owners.

SOURCE Futuremedia plc


CONTACT: Mike Smargiassi or Corey Kinger, Brainerd Communicators, Inc.
+1-212-986-6667,
ir@futuremedia.co.uk, for Futuremedia plc

URL: http://www.prnewswire.com
http://www.ukhomecomputing.co.uk
www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

-0-


KEYWORD: England
INDUSTRY KEYWORD: CPR
EDU
MLM
FIN
HOU

*** end of story ***

Keep an eye on GTEL

(COMTEX) B: The Business Press, San Bernardino, Calif., technology column
B: The Business Press, San Bernardino, Calif., technology column

Apr 11, 2005 (The Business Press - Knight Ridder/Tribune Business News via
COMTEX) -- Local firm to unveil 'wireless' airship

Sanswire Networks LLC in San Bernardino is unveiling a prototype April 12 of its
high-altitude airship that will launch later this year to rain cellular, voice,
data and video signals over 126,000 square miles. Sanswire, a wholly-owned
subsidiary of GlobeTel Communications Corp. in Pembroke Pines, Fla. (Nasdaq:
GTEL), ultimately wants to launch "thousands" of the 300 to 400 foot-long
airships to function as high-altitude telecommunications platforms, Leigh
Coleman, GlobeTel's president, said April 7.

"They're a lot cheaper than satellites. They are satellite replacement
vehicles," he said.

The company hopes to launch the ship from Edwards Air Force Base in July or
August, contingent on approvals from regulating agencies, he said.

Sanswire will transport attendees of the April 12 unveiling from the San
Bernardino Hilton to its hangar at San Bernardino International Airport, where
50 to 60 employees have constructed the prototype ship called Sanswire One.

The prototype ship is 50 feet high, 60 feet wide and just under 200 feet long,
Coleman said.

Sanswire plans to build the Sanswire Two full-size ship in Palmdale and launch
the craft from Edwards. The ship, at 400 feet long, will be constructed of
aluminum and will blast to 65,000 feet above the earth.

The ships will float for approximately 18 months before being returned for
upgrades with the latest technology.

The company is looking to hire individuals with aerospace and lightweight
construction experience.

Sanswire plans to build "very large" manufacturing facilities for the ships,
Coleman said.

"Our plans are to launch at Edwards Air Force Base under the direction of NASA
and the Air Force. Each agency will have to approve the flight plan before the
launch date. By launching it from Edwards, we will be using non-FAA regulated
air space which should expedite the flight safety approval process," Timothy M.
Huff, GlobeTel's chief executive officer, said in a release.

Coleman declined to reveal the costs associated with Sanswire One or its funding
sources.

Sanwire parent company GlobeTel is an international telecommunications firm
specializing in voice-over-IP, international telecommunications services and
wireless bank account access via mobile phones.

GlobeTel has 30,000 shareholders.

Federal nabs servers

Federal Edge Inc., a Riverside company that provides computers, electronic data
storage, three-dimensional computer graphics and other technology to federal,
state and local governments, has agreed to re-sell a Carlsbad firm's network and
computer server backup products.

Arkeia Corp. in Carlsbad announced the deal April 4. Arkeia provides computer
file backup and recovery products for offices that use Linux systems.

"Being able to provide our government and military customers with complete data
protection for their Linux and UNIX servers is an important differentiator for
us," Cindra Stolk, Federal Edge's president, said in a release.

The deal will broaden Arkeia's market share, particularly among federal
agencies, Rick DiViesti, Arkeia's director of sales, said in the release.

The Arkeia Network Backup features 64-bit Linux support for Intel, Itanium and
support of Kernel 2.6 Linux distributions. Arkeia Server Backup works with tape
autoloaders.

Darla Martin Tucker at (909) 806-3112 or dtucker@the bizpress.com


By Darla Martin Tucker
To see more of The Business Press, or to subscribe to the newspaper, go to
http://www.thebizpress.com.

Copyright (c) 2005, The Business Press, San Bernardino, Calif.

-0-



*** end of story ***

Walk, FMDAY hit my stop loss one again when she hit .40 took a whoopen this round.

PPHM on the other hand is making me some nice profits.

Secure, I am still holding from .50 Can't see FMDAY dropping anymore then it already did..IMO

Congrats on the new grandkid. Now just think of all that spoiling your going to get to do..LOL

Walk, FMDAY is still on stand by but I am watching her close. Now PPHM made on heck of a run from 1.25 Hope you guys got in on that one and took very good profit.

Secure, I was not sure anyone was following this stock with me but it has made some very good profit over the last few months. As you know PPHM and FMDAY are my two best stocks to play. In case you missed the news yesterday here it is:

(PR NEWSWIRE) Journal of Clinical Oncology Publishes Significant Anti-Tumor Act
vity of Tumor Necrosis Therapy for Treating Patients
Journal of Clinical Oncology Publishes Significant Anti-Tumor Activity of Tumor
ecrosis Therapy for Treating Patients With Advanced Lung Cancer

TUSTIN, Calif., March 2 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today the publication of data
in the Journal of Clinical Oncology demonstrating significant anti-tumor
activity in a study of 107 patients with advanced lung cancer treated at eight
oncology centers in China with an iodine-131 radiolabeled Tumor Necrosis
Therapy antibody (131I-TNT). In the published article, approximately 90% of
patients treated with 131I-TNT had stable disease or better with 3.7%
achieving complete responses, 30.8% achieving partial responses involving at
least 50% shrinkage of their tumors and 55.1% achieving stable disease
(representing no change in the tumor mass). The Objective Response Rate (ORR)
to the therapy was 34.6% as measured by World Health Organization criteria
(WHO).
According to the study, radioimmunotherapy with Iodine-131 chimeric TNT
was well tolerated and can be used intravenously or intratumorally to treat
refractory tumors of the lung. While the overall response rate in patients
treated intravenously and intratumorally were approximately 36% and 33%,
respectively, the severity of side effects related to the drug was lower in
patients treated intratumorally. ORR was defined according to WHO criteria
for measuring solid tumors as patients with a complete response defined as
disappearance of all known lesion(s), or partial response defined as at least
a 50% decrease; confirmed at four weeks.
"The publication of this data in the Journal of Clinical Oncology affirms
the TNT approach to treating lung cancer," said Steven King, president and CEO
of Peregrine. "The recent completion of enrollment in a Phase I safety study
using our similar product Cotara(R), along with this promising data in the
treatment of lung cancer, opens the possibility for similar trials in the
U.S."
"This compelling tumor response data in advanced lung cancer and the
clinical data we have generated in brain cancer demonstrate TNT's ability to
clinically benefit people suffering from cancer," stated Joe Shan, Director of
Clinical Development at Peregrine Pharmaceuticals. "We are looking forward to
initiating clinical enrollment in our brain cancer trial in collaboration with
the New Approaches to Brain Tumor Therapy consortium."
About Cotara(R) and Tumor Necrosis Therapy (TNT) Platform
The company is developing a radioactive chimeric TNT antibody that it has
trademarked Cotara(R) for the treatment of cancer. Cotara(R) is designed to
bind to the dead or dying tissue within the tumor and, once bound, its
radioisotope irradiates nearby cells resulting in the death of nearby tumor
cells.
Rapidly growing tumors quickly outgrow their blood supply resulting in a
region of tumor cells that do not receive adequate oxygen, nutrients and waste
removal. The accumulation of dying cells results in the formation of a dead,
or necrotic, core present in virtually all solid tumors beyond a very small
size. TNT-based products directly target and bind to dead and dying tumor
cells found in virtually all solid tumors. By using the necrotic core as a
stable anchorage in the heart of a tumor, TNT-based therapeutic agents have
the potential to deliver therapeutic agents preferentially targeted to
virtually all solid tumors, including brain, lung, colon, breast, liver,
prostate and pancreatic cancers.
The company is working with New Approaches to Brain Tumor Therapy (NABTT)
Consortium to initiate the first part of Peregrine's U.S. Food and Drug
Administration (FDA)-approved product registration trial using Cotara(R) to
treat patients with brain cancer. Peregrine has also completed enrollment in a
Phase I Cotara(R) clinical trial for the treatment of colorectal carcinoma at
Stanford University Medical Center and is working closely with scientific
advisors to design Phase II studies using Cotara(R) for other solid tumor
indications. In addition, a TNT-based agent similar to Cotara(R) was developed
under a licensing agreement in China and has received marketing approval for
the treatment of advanced lung cancer.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals (Peregrine) is a biopharmaceutical company
primarily engaged in the research, development, manufacture and
commercialization of cancer therapeutics and diagnostics through a series of
proprietary platform technologies. The company is primarily focused on
discovering and developing products that affect blood vessels and blood flow
in cancer and other diseases. Peregrine's vascular research programs fall
under several different proprietary platforms, including Anti-Phospholipid
Therapy (APT), Vascular Targeting Agents (VTAs), Anti-Angiogenesis and
Vasopermeation Enhancement Agents (VEAs).
Peregrine recently received approval from the FDA for its Tarvacin(TM)
Phase I study for the treatment of cancer. Tarvacin(TM), a novel anti-cancer
agent, is part of Peregrine's Anti-Phospholipid Therapy (APT) platform, which
binds directly to tumor blood vessels to inhibit tumor growth and development.
The company plans on initiating the approved Phase I study in the near term.
For other recent news or additional information about the company, please
visit http://www.peregrineinc.com .
Safe Harbor Statement: This release may contain certain forward-looking
statements that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Except for historical information
presented herein, matters discussed in this release contain certain forward-
looking statements. The inclusion of forward-looking statements should not be
regarded as a representation by us, or any other person, that the objectives
or plans will be achieved. The words "may," "should," "plans," "believe,"
"anticipate," "estimate," "expect," their opposites and similar expressions
are intended to identify forward-looking statements. We caution readers that
such statements are not guarantees of future performance or events and are
subject to a number of factors that may tend to influence the accuracy of the
statements, including but not limited to, risk factors discussed in
Peregrine's report on Form 10-K for the year ended April 30, 2004 and
subsequent quarterly reports on Form 10-Q. Peregrine disclaims any obligation
and does not undertake to update or revise the forward-looking statements
discussed in this press release.
Investor Inquiries
Hawk Associates, Inc.
Frank Hawkins and Ken AuYeung
(800) 987-8256
info@hawkassociates.com

Media Inquiries
Rachel Martin
Edelman
(323) 202-1031/(323) 893-1047
Rachel.Martin@edelman.com
SOURCE Peregrine Pharmaceuticals, Inc.


Contact Information:
Investor, Frank Hawkins and Ken AuYeung, both of Hawk Associates, Inc., +1-800-9
7-8256, or info@hawkassociates.com; or Media, Rachel Martin of Edelman, +1-323-2
2-1031 or +1-323-893-1047, or Rachel.Martin@edelman.com, all for Peregrine Pharm
ceuticals

WebSite:
http://www.peregrineinc.com
*** end of story ***

PPHM making a nice move this morning.

PPHM up 7 cents this morning.

Good call Lin.

Yes sir FMDAY is on her way back up now. Lets rock & roll.

Lets just hope the PPHM news does not kill it like FMDAY news did.

PPHM is holding up real good from last week:

(COMTEX) B: Peregrine Pharmaceuticals Presents Data at 7th International S
mposium on Anti-Angiogenic Agents Human 2C3 Equivalen
B: Peregrine Pharmaceuticals Presents Data at 7th International Symposium on Ant
-Angiogenic Agents Human 2C3 Equivalents Presented at Conference ( PRNewswire-Fi
stCall )

TUSTIN, Calif., Feb 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that data relating to the
production and characterization of human antibody versions of its 2C3 antibody
was presented at the 7th International Symposium on Anti-Angiogenic Agents held
in La Jolla, CA.

The 2C3 antibody is a mouse antibody that selectively blocks certain activities
of the blood vessel growth factor known as Vascular Endothelial Growth Factor
(VEGF). VEGF has been implicated as a key factor in the development of a variety
of different diseases including cancer and various ocular disorders. The human
antibodies are intended to be used in Peregrine's Vascular Targeting Agent (VTA)
and anti-angiogenesis programs.

"The successful generation of these human antibodies is a key milestone in the
continued development of our pre-clinical pipeline of products," said Steven
King, Peregrine's president and CEO. "Having these human 2C3 equivalent
antibodies should expedite the identification of clinical candidates based on
this targeting platform."

In pre-clinical studies, 2C3 has shown potent anti-tumor activity in a variety
of different solid tumors including an 85% reduction in blood vessel formation
in breast cancer metastases. Affitech AS of Oslo, Norway generated the human 2C3
equivalent antibodies in collaboration with Peregrine.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals (Peregrine) is a biopharmaceutical company primarily
engaged in the research, development, manufacture and commercialization of
cancer therapeutics and diagnostics through a series of proprietary platform
technologies. The company is primarily focused on discovering and developing
products that affect blood vessels and blood flow in cancer and other diseases.
Peregrine's vascular research programs fall under several different proprietary
platforms, including Anti-Phospholipid Therapy (APT), Vascular Targeting Agents
(VTAs), Anti-Angiogenesis and Vasopermeation Enhancement Agents (VEAs).

Peregrine recently received approval from the FDA for its Tarvacin(TM) Phase I
study for the treatment of cancer. Tarvacin, a novel anti-cancer agent, is part
of Peregrine's Anti-Phospholipid Therapy (APT) platform, which binds directly to
tumor blood vessels to inhibit tumor growth and development. The company plans
on initiating the approved Phase I study in the near term.

Peregrine's most clinically advanced therapeutic program is known as Tumor
Necrosis Therapy (TNT) and targets dead or dying tumor cells that are common to
the majority of different tumor types. The company is developing a radioactive
TNT agent that it has trademarked Cotara(R) for the treatment of cancer. The
company is working with New Approaches to Brain Tumor Therapy (NABTT) Consortium
to initiate the first part of Peregrine's U.S. Food and Drug Administration
(FDA)-approved product registration trial using Cotara(R) to treat patients with
brain cancer. Peregrine has also completed enrollment in a Phase I Cotara(R)
clinical trial for the treatment of colorectal carcinoma at Stanford University
Medical Center and is working closely with scientific advisors to design Phase
II studies using Cotara(R) for other solid tumor indications. In addition, a
TNT-based agent similar to Cotara(R) was developed under a licensing agreement
in China and has received marketing approval for the treatment of advanced lung
cancer.

The company's wholly owned subsidiary, Avid Bioservices, Inc. (
http://www.avidbio.com ), develops and manufactures monoclonal antibodies and
recombinant proteins to support Phase I through Phase III clinical trials for
biotechnology companies, including Peregrine.

Copies of Peregrine press releases, SEC filings, current price quotes and other
valuable information for investors may be found at http://www.peregrineinc.com .

Safe Harbor Statement: This release may contain certain forward-looking
statements that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Except for historical information
presented herein, matters discussed in this release contain certain forward-
looking statements. The inclusion of forward-looking statements should not be
regarded as a representation by us, or any other person, that the objectives or
plans will be achieved. The words "may," "should," "plans," "believe,"
"anticipate," "estimate," "expect," their opposites and similar expressions are
intended to identify forward-looking statements. We caution readers that such
statements are not guarantees of future performance or events and are subject to
a number of factors that may tend to influence the accuracy of the statements,
including but not limited to, risk factors discussed in Peregrine's report on
Form 10-K for the year ended April 30, 2004 and subsequent quarterly reports on
Form 10-Q. Peregrine disclaims any obligation and does not undertake to update
or revise the forward-looking statements discussed in this press release.


Investor Inquiries
Hawk Associates, Inc.
Frank Hawkins and Julie Marshall
(800) 987-8256 or
info@hawkassociates.com

Media Inquiries
Lorie Fiber
Edelman
(323) 202-1046/310-383-6583 (cell)
lorie.fiber@edelman.com

SOURCE Peregrine Pharmaceuticals, Inc.


CONTACT: Investors, Frank Hawkins or Julie Marshall, both of Hawk Asso
iates, Inc.,
+1-800-987-8256 or info@hawkassociates.com, or Media, Lorie F
ber, Edelman,
+1-323-202-1046, or cell, +1-310-383-6583, or lorie.fiber@ede
man.com, all for
Peregrine Pharmaceuticals, Inc.

URL: http://www.prnewswire.com
http://www.peregrineinc.com
http://www.avidbio.com
www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

-0-


KEYWORD: California
INDUSTRY KEYWORD: HEA
MTC
SUBJECT CODE: TDS
SVY

*** end of story ***

Anyone still playing PPHM? She is on the move today.

FMDAY just hit my stop. Lets see how low she will go this time.

FMDAY is just about to hit my stop. I thought for sure she would have spiked up from the major drop in price. Still holding mine from .65

News sure dropped FMDAY. I got back in at .65 to see what happens.

(InternetWire) BWR Begins Due Diligence on HOFF, BCON, FORD and FMDAY
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bell
ether Report.


TORONTO -- (MARKET WIRE) -- 02/03/05 -- The Bellwether Report has identified an
added
these four aggressive growth opportunities to our "Stocks of Interest"
Horizon Offshore (NASDAQ: HOFF), Beacon Power Corp (NASDAQ: FMDAY), Forward
Industries (NASDAQ: FORD) and Futuremedia PLC (NASDAQ: FMDAY). Our
analysts will be watching the companies listed below, over the course of
trading, as in each case they have flown out of the gates in early activity
this morning.





BWR will be researching the developments that came to fruition before the
Bell with the following companies to gauge the long-term and short-term
effects of their most recent market correction. If you would like to view
the full report on any of the above-mentioned companies, feel free to visit
www.bellwetherreport.com for a free 30-day complimentary subscription.



Horizon Offshore is trading up 16% today on much higher than their average
3-month volume. BWR is looking into this most recent market correction to
see where the sudden influx in demand is being generated from. The
company's last corporate development came on January 21st, 2005, and
therefore BWR feels that the company will need to materialize on some solid
corporate developments to justify their current market position.



Beacon Power Corp is also trading up 15% today on much higher than average
volume. BWR also believes that the company will need to materialize on some
corporate developments in order to sustain their current levels.



Forward Industries has made a significant jump today at one point trading
up over $1.00 from their previous close. The company's volume is being
stimulated on what we believe is speculation of a positive corporate
development, as they have already traded 2.1 million shares today.



FutureMedia PLC is making its way back off their bottom today. The company
has been sitting very close to their 52 week low of $.65, but today are
trading up 13%. BWR will be researching developments with the company to
see what the likelihood of a turnaround is.



If you would like to receive all corporate updates on the company, feel
free to visit www.bellwetherreport.com for a 1-month complimentary
subscription.



The Bellwether Report is not compensated by any of the above-mentioned
companies.



For more information contact:
The Bellwether Report
1 866 702 5511
Support@bellwetherreport.com




*** end of story ***

FMDAY NEWS:

(InternetWire) Futuremedia Awarded Major E-Learning Contract by UK Crown Prosecu
ion Service

BRIGHTON, UK -- (MARKET WIRE) -- 02/03/05 -- The UK Crown Prosecution Service (
PS) has
awarded a two-year contract to Futuremedia (NASDAQ: FMDAY) to develop
customised courses for the CPS's Learning and Development Department. The
contract provides for an initial payment of up to GBP 350,000 (US$ 655,000)
expected upon delivery of the first order, currently anticipated for the
end of March 2005, and could result in additional revenues over the
duration depending on the number of courses developed.



Courses will include Law, Leadership and Management, Business Support and
Personal Development. Part of the content is the Lawyers Induction,
directed at new lawyers joining the CPS. As part of their initial training,
new lawyers will be able to take part in modules covering the Code for
Crown Prosecutors, and the Police And Criminal Evidence Act (PACE), which
includes powers of arrest and identification, the Bail Act, and custody
time limits.





Leonard M. Fertig, Chief Executive Officer of Futuremedia, commented: "We
are delighted to have been chosen to work with the Crown Prosecution
Service on this exciting new initiative to benefit professional
development. During the tendering process we faced stiff competition, but
we believe that Futuremedia's experience and quality offering in this field
led to the awarding of the contract. As one of the UK's key front line
civil service departments, the CPS is a good example of the use and
benefits of e-learning."



Shelagh O'Leary, Crown Prosecution Service, added: "Following the success
of our first programme on vulnerable witnesses called 'Speaking Up for
Justice,' we wanted significantly to increase the availability of
CPS-specific e-learning for our staff. Futuremedia provided us with
excellent advice, support and resources throughout the whole project and is
considered a valued and trusted partner, with whom we will continue to
develop our e-learning offering."



About the Crown Prosecution Service



The Crown Prosecution Service is responsible for prosecuting people in
England and Wales who have been charged by the police with a criminal
offence.
This role includes:

- advising the police on possible prosecutions
- reviewing prosecutions started by the police (to make sure the
right defendants are prosecuted on the right charges)
- preparing cases for court
- prosecuting cases at the Magistrates Court
- instructing counsel to prosecute in the Crown Court and higher courts.

More information can be found on http://www.cps.gov.uk.



About Futuremedia



Futuremedia is a leading company in the e-Learning market with 20 years
experience in providing technology-based solutions to public and private
sector organisations. Services include: learning consultancy, custom made
learning programmes, an extensive library of published courseware titles
and needs analysis and follow up of individual employees. Futuremedia has
developed Aktivna, a full suite of Learning Management Solutions, and ELSA,
an interactive learning system.



Futuremedia's customers include Britvic, BT, BUPA, Capita, Channel Four,
Daimler Chrysler, GSK, Hilton International, IDEA, ING Direct, the UK
National Health Service, Royal Mail, Syngenta, Winterthur Life and a
growing number of UK local authorities. The Company is partnered with
Fujitsu-Siemens, Microsoft, Thomson NETg and SkillSoft in delivering its
products and solutions.



More information is available on www.futuremedia.co.uk.



"Safe Harbor" Statement under Section 21E of the Securities Exchange Act of
1934: This press release contains forward-looking statements related to
future results and speaks only of Futuremedia's expectations as of the date
hereof. Such statements include discussions concerning the Company's future
financial performance and the future performance of the Company's products.
Such statements involve known and unknown risks and uncertainties that may
cause actual results to differ materially from expectations. The risks and
uncertainties include the Company's ability to develop and successfully
market new services and products, the risk that customer contracts (such as
the UK CPS contract) may be terminated or not completed in whole or in part
due to factors beyond the Company's control, the Company's ability to
continue to increase revenue and generate cash, the Company's ability to
operate profitably in the future, the management of growth, the early stage
of the Internet and intranet learning and communications market, rapid
technological change and competition, and other factors detailed in the
Company's filings with the US Securities and Exchange Commission. The
Company expressly disclaims any obligation to release publicly any updates
or revisions to any such statement to reflect any change in expectations or
in information on which any such statement is based. All product names and
trademarks mentioned herein are trademarks of Futuremedia or their
respective owners.



Contact Information:
Futuremedia plc, Brighton, UK
Leonard M. Fertig
CEO
+44-1273-829-700

Annemieke Blondeel
IR for Futuremedia
+44-1308-863-871
ir@futuremedia.co.uk




*** end of story ***

PPHM on fire this morning with news:

(COMTEX) B: Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Co
sortium Receive Approval for Cotara(R) Brain Cancer P
B: Peregrine and New Approaches to Brain Tumor Therapy (NABTT) Consortium Receiv
Approval for Cotara(R) Brain Cancer Protocol ( PRNewswire-FirstCall )

TUSTIN, Calif., Jan 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM) and the New Approaches to Brain Tumor
Therapy Consortium announced today that they have received approval from the NCI
for their clinical protocol to treat Glioblastoma Multiforme, a deadly form of
brain cancer, using Cotara(R). The protocol was approved by the Protocol Review
Committee of the NCI Cancer Therapy Evaluation Program (CTEP). Peregrine and
NABTT are currently in the process of initiating the multi- center study at
participating institutions.

The NCI-approved protocol, titled "An Open-Label, Dose Confirmation and
Dosimetry Study of Interstitial 131I-chTNT-1/B (Cotara)(R) for the Treatment of
Glioblastoma Multiforme at 1st or 2nd Relapse," will evaluate safety, radiation
exposure and efficacy of a single dose of Cotara(R).

Prior Phase I and Phase II brain cancer studies examined safety and efficacy of
Cotara(R) administered through single or multiple infusions. Data from these two
studies indicated that safety and efficacy were related to total radioactive
dose delivered rather than the number of infusions used to deliver the drug.
Based on this information, Peregrine designed the current protocol using a
single dose, which enhances patient convenience and simultaneously lowers the
overall cost of manufacturing and related expenses. The approved protocol
represents the first part of Peregrine's FDA-approved product registration
clinical trial for Cotara(R).

About Cotara(R) and Tumor Necrosis Therapy (TNT)

Cotara(R) is the registered trademark for a chimeric TNT antibody attached to
Iodine 131, a radioactive agent. Cotara(R) is designed to bind to the dead or
dying tissue within the tumor and, once bound, its radioisotope irradiates
nearby cells resulting in the death of nearby tumor cells.

Rapidly growing tumors quickly outgrow their blood supply resulting in a region
of tumor cells that do not receive adequate oxygen, nutrients and waste removal.
The accumulation of dying cells results in the formation of a dead, or necrotic,
core present in virtually all solid tumors beyond a very small size. TNT-based
products directly target and bind to dead and dying tumor cells found in
virtually all solid tumors. By using the necrotic core as a stable anchorage in
the heart of a tumor, TNT-based therapeutic agents have the potential to deliver
therapeutic agents preferentially targeted to virtually all solid tumors,
including brain, lung, colon, breast, liver, prostate and pancreatic cancers.

About NABTT

The primary objective of the New Approaches to Brain Tumor Therapy (NABTT) CNS
Consortium is to improve the therapeutic outcome for adults with primary brain
tumors. This consortium is one of two nationwide that is funded by the National
Cancer Institute to conduct Phase I and II clinical evaluations of promising new
treatment strategies (surgery, radiation, chemotherapy, and biologic therapies),
routes of administration, and clinical trial design in the treatment of primary
malignancies of the central nervous system. The NABTT CNS Consortium is
specifically designed to combine and focus the experience, resources, and
capabilities of nine outstanding medical institutions (Emory University,
Cleveland Clinic, Henry Ford Hospital, Johns Hopkins University, Mass General
Hospital, Moffitt Cancer Center, NCI Neuro- Oncology Intramural Program,
University of Alabama, University of Pennsylvania, Wake Forest University) to
bear on primary brain tumors. Additional information about NABTT can be found at
http://www.nabtt.org .

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals is a biopharmaceutical company primarily engaged in
the research, development, manufacture and commercialization of cancer
therapeutics and diagnostics through a series of proprietary platform
technologies. The company is primarily focused on discovering and developing
products that affect blood vessels and blood flow in cancer and other diseases.
Peregrine's vascular research programs fall under several different proprietary
platforms, including Anti-Phospholipid Therapy (APT), Vascular Targeting Agents
(VTAs), Anti-Angiogenesis and Vasopermeation Enhancement Agents (VEAs). The
company is working closely with the U.S. Food and Drug Administration (FDA) to
initiate its first clinical trial under its APT program using Tarvacin(TM).
Tarvacin(TM) is an antibody that binds to the phospholipid, phosphatidylserine,
which binds directly to tumor blood vessels to inhibit tumor growth and
development.

Peregrine's most clinically advanced therapeutic program is known as Tumor
Necrosis Therapy (TNT) and targets dead or dying tumor cells that are common to
the majority of different tumor types. The company is developing a radioactive
TNT agent that it has trademarked Cotara(R) for the treatment of cancer. The
company is working with New Approaches to Brain Tumor Therapy (NABTT) Consortium

to initiate the first part of Peregrine's U.S. Food and Drug Administration
(FDA)-approved product registration trial using Cotara(R) to treat patients with
brain cancer. Peregrine has also completed enrollment in a Phase I Cotara(R)
clinical trial for the treatment of colorectal carcinoma at Stanford University
Medical Center and is working closely with scientific advisors to design Phase
II studies using Cotara(R) for other solid tumor indications. In addition, a
TNT-based agent similar to Cotara(R) was developed under a licensing agreement
in China and has received marketing approval for the treatment of advanced lung
cancer.

The company's wholly owned subsidiary, Avid Bioservices, Inc. (
http://www.avidbio.com ), develops and manufactures monoclonal antibodies and
recombinant proteins to support Phase I through Phase III clinical trials for
biotechnology companies, including Peregrine.

Copies of Peregrine press releases, SEC filings, current price quotes and other
valuable information for investors may be found at http://www.peregrineinc.com .

Safe Harbor Statement: This release may contain certain forward-looking
statements that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Except for historical information
presented herein, matters discussed in this release contain certain forward-
looking statements. The inclusion of forward-looking statements should not be
regarded as a representation by us, or any other person, that the objectives or
plans will be achieved. The words "may," "should," "plans," "believe,"
"anticipate," "estimate," "expect," their opposites and similar expressions are
intended to identify forward-looking statements. We caution readers that such
statements are not guarantees of future performance or events and are subject to
a number of factors that may tend to influence the accuracy of the statements,
including but not limited to, risk factors discussed in Peregrine's report on
Form 10-K for the year ended April 30, 2004 and subsequent quarterly reports on
Form 10-Q. Peregrine disclaims any obligation and does not undertake to update
or revise the forward-looking statements discussed in this press release.


Investor Inquiries
Hawk Associates, Inc.
Frank Hawkins and Ken AuYeung
(800) 987-8256
info@hawkassociates.com

Media Inquiries
Lorie Fiber
Edelman
(323) 202-1046/310-383-6583 (cell)
lorie.fiber@edelman.com

SOURCE Peregrine Pharmaceuticals, Inc.


CONTACT: Investors, Frank Hawkins and Ken AuYeung, Hawk Associates, In
., +1-800-987-8256, or
info@hawkassociates.com; or Media, Lorie Fiber, Edelman, +1-3
3-202-1046, or
cellular, +1-310-383-6583, or lorie.fiber@edelman.com, all fo
Peregrine
Pharmaceuticals, Inc.

URL: http://www.prnewswire.com
http://www.peregrineinc.com
http://www.nabtt.org
www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

-0-


KEYWORD: California
INDUSTRY KEYWORD: HEA
MTC
SUBJECT CODE: SVY

*** end of story ***

Nice call dsertrat. News from the 6th looks promising:

(COMTEX) B: Motorsports Emporium 2005 Strategy Already in High Gear; Plann
B: Motorsports Emporium 2005 Strategy Already in High Gear; Planned Activities o

SCOTTSDALE, Ariz., Jan 6, 2005 (BUSINESS WIRE) -- David Keaveney, CEO of
Motorsports Emporium, Inc. (OTCBB:MSEP) announced today that the company is
already implementing its strategic plan for 2005 in the motor sports industry
after experiencing better than expected Christmas season sales at its retail
store and website.

The company's strategic objective is to increase gross revenues to $1,000,000 -
$5,000,000 in 2005 by adding new business divisions, improving its competitive
advantage, expanding its current customer base and offering new and existing
customers more products to buy and enjoy.

With the recent appointment of David Keaveney as President & CEO, MSEP has
positioned itself for tremendous growth. Through the direction of Mr. Keaveney,
MSEP has acquired the assets of www.scalecars.com, divested itself of its gaming
subsidiary, and redirected the company efforts into opportunities within the
motor sports industry. Should the company successfully execute its strategic
objectives, MotorSports Emporium, Inc. could have a record year in terms of
financial results and shareholder value.

Mr. Keaveney commented, "I want to thank all of our shareholders, friends and
family of Motorsports Emporium who have welcomed and supported my efforts to
redirect the company into the fastest-growing spectator sport in America today -
Auto and Motor Sports. To help the investment community understand the company's
direction I have included key elements of our strategic plan in this press
release. I expect to implement as much of this plan as possible given the
available capital, market opportunities and resources available. 2005 should be
a very exciting year and I look forward to leading MSEP to new success."


Key elements of the 2005 Strategic Plan include:

Business

Several new divisions are planned to enhance the rollout of our 2005 growth
strategy. Included is a website portal to an online automotive parts dealer,
title sponsorship of a race team, distribution of new and diverse product lines
and exclusive or co-operative licensing agreements with race drivers to
manufacture and sell merchandise and products.

Advisory Board

MotorSports Emporium, Inc. will also establish an advisory board of outside
advisors with detailed knowledge of the motor sports industry. Each advisor is
chosen based on his/her competency to contribute ideas and past successes to
help the business cope with existing circumstances and adapt to new ones.
Members of the advisory board will be instrumental in opening doors for the
company and breaking down barriers of entry to new opportunities.

Market Opportunity

There are more than 100 million racing enthusiasts in the United States and
one-in-three adults consider themselves race fans. Of these, 40% spend nine or
more hours per week on race related activities. These fans are the most
brand-loyal of all sports fans with 70% loyalty to race sponsors. Auto racing is
the fastest growing spectator sport and is second only to the NFL in popularity.
MotorSports Emporium, Inc. taps directly into the passion of this market with
its planned products and services.

Competitive Advantage

MotorSports Emporium, Inc. is implementing a robust business strategy to
directly grow the business into a multi million-dollar company. Already, our
subsidiary, ScaleCars.com has established itself as a trustworthy and reputable
company with loyal customers. MSEP is focused and very receptive of consumer
demographics, expansion and trends. Our strategic business model incorporates a
storefront, robust Internet site, trackside events, catalog sales, diversity of
products and innovation of co-operative licensing agreements and sponsorship.

MSEP Business Rollout Strategy Q1 - Q4 2005

MotorSports Emporium, Inc has a focused vision for 2005 with an objective to
increase gross revenues to $1,000,000 - $5,000,000.

Trackside and Special Events: In 2003 more than 7 million people attended motor
sports events. From our due diligence we've discovered a successful manufacturer
& merchandiser of die cast cars and memorabilia generated over $60 million from
trackside events. The company plans to enter trackside events as part of its
strategic business model to increase gross revenues.

Retail Store and Internet: Scalecars.com occupies 2,900 sq ft of which 900 sq ft
is used as retail space. To welcome retail customers and impact sales,
ScaleCars.com will host a variety of local events in and around the store. The
premier ScaleCars.com web site is currently being upgraded to include easy
navigation to promote specials, giveaways and valuable links to race events, car
shows, car clubs and a chat site. Additionally we will establish magazine
advertisements and television commercials as well as market a quarterly product
catalog, and provide monthly sales/specials, establish gift cards and weekly
email campaigns

Licensing Agreements: Through professional race drivers, team owners and
sponsors, MSEP seeks to engage licensing agreements to manufacture, wholesale
and retail specialty product lines based on a specific driver, and/or team.
Depending upon the popularity of the drivers, the exclusivity of the licensing
and distribution channels, MSEP could expects the business of wholesale
manufacturing and licensing to play an important role of revenue growth in 2005.

Keaveney concluded by saying, "We've already begun executing our 2005 strategic
plan and will update the investment community as we accomplish key milestones. I
am truly excited about this industry and the opportunities before us. As always
I appreciate your support and continued trust in management and the future of
MotorSports Emporium, Inc. and its subsidiaries."

About Motorsports Emporium

Motorsports Emporium, Inc. (OTCBB:MSEP) is a fast track new company in the Motor
Sports industry targeting amateur and professional enthusiasts who participate
in die cast collecting, automobile restoration, high performance accessories,
race venues and product licensing. To purchase products visit www.ScaleCars.com
or for further information about MotorSports Emporium, Inc. contact: Mark
Wolkos, at (480) 556-0821.

This news release may include forward-looking statements within the meaning of
section 27A of the United States Securities Act of 1933, as amended, and section
21E of the United States Securities and Exchange Act of 1934, as amended, with
respect to achieving corporate objectives, developing additional project
interests, the company's analysis of opportunities in the acquisition and
development of various project interests and certain other matters. These
statements are made under the "Safe Harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995 and involve risks and
uncertainties which could cause actual results to differ materially from those
in the forward-looking statements contained herein.

SOURCE: Motorsports Emporium, Inc.


CONTACT: Motorsports Emporium, Inc.
Mark Wolkos, 480-556-0821


Copyright (C) 2005 Business Wire. All rights reserved.

-0-


KEYWORD: ARIZONA
INDUSTRY KEYWORD: AUTOMOTIVE
RETAIL
SPORTS
INTERNET
E-COMMERCE
Copyright
Business
Wire
2005

*** end of story ***

Good move Walk. I think you got in at the right price.IMO

PPHM on the move from $1.04

WTG Walk. Now what will ya do for the rest of the week? LOL

Nice call Lin.

PPHM hit my stop loss. One dead one to start the year off with.

I hear ya SS. My two picks for the new year have not done anything. Heck one dropped in price but came back up. Still holding and hoping.

SS, Very well said my friend. We have a great group of guys here that have made some very good calls. We all work together as a team to make a buck here and there. Lets hope 2005 will be the year we have been waiting for.

Trying PPHM @ $1.18 to see what happens.

Hey gang. Hope everybody had great holiday's. I have started the year off with FMDAY at .85 to see what she will do. I hope this year we all make a killing off the market. I want to thank each and everyone of you for all your hard work you have put into this board helping others to make money. Now lets kick 2005 off with a nice profit.

Hey guys and gals. Just wanted to stop in to see how things are going. I hope everyone had a Merry Christmas? I will be gone most of this week so no market for me until next year. I want to wish each and everyone of you a Happy New Year and please be safe out there. May 2005 be a better year for us in the market.

Watching her close here. .80 has been the get in range for me but I have my finger on the trigger.

Anytime Knobias puts out any PR you can look for that stock to drop. FMDAY hit my stop loss at $1.06 now I am waiting to see what their next step will be.